Price T Rowe Associates Inc Replimune Group, Inc. Transaction History
Price T Rowe Associates Inc
- $869 Billion
- Q3 2024
A detailed history of Price T Rowe Associates Inc transactions in Replimune Group, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 9,879,250 shares of REPL stock, worth $123 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
9,879,250
Previous 9,236,057
6.96%
Holding current value
$123 Million
Previous $83.1 Million
30.26%
% of portfolio
0.01%
Previous 0.01%
Shares
16 transactions
Others Institutions Holding REPL
# of Institutions
149Shares Held
68MCall Options Held
52.3KPut Options Held
80.3K-
Baker Bros. Advisors LP New York, NY11MShares$138 Million1.3% of portfolio
-
Fcpm Iii Services B.V. Naarden, P74.87MShares$60.8 Million9.16% of portfolio
-
Redmile Group, LLC San Francisco, CA4.78MShares$59.7 Million3.43% of portfolio
-
Black Rock Inc. New York, NY4.71MShares$58.9 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.47MShares$43.3 Million0.0% of portfolio
About Replimune Group, Inc.
- Ticker REPL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,306,700
- Market Cap $616M
- Description
- Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes ...